
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb is well-positioned for future growth with strong performance in the SiHy lens and premium intraocular lens markets, as well as a promising pipeline of new products. The company's separation from Bausch Health in 2022 allows for a focused approach to eyecare and potential expansion in global markets. With a successful CFO and a new product in development, Bausch & Lomb has the potential to continue its revenue growth in the coming years.
Bears say
Bausch & Lomb is facing several fundamental risks that may negatively impact its future growth and profitability. Weak consumer demand and the company's exposure to broader economic conditions may lead to lower sales volumes and revenue. Additionally, the company's high valuation and ownership stake by parent company Bausch Health may continue to be a hindrance to its stock performance. While Bausch & Lomb's diverse portfolio and expansion in areas such as premium intraocular lenses and ophthalmic pharmaceuticals provide some growth potential, any underperformance in key areas such as MIEBO sales or contact lens demand could lead to a downward revision of revenue expectations.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares